SHOW DIRECTORY
All-In
Industry veterans Chamath Palihapitiya, Jason Calacanis, David Sacks, and David Friedberg cover economics, technology, politics, society, and poker.
SOURCE DESCRIPTION · RSS
They're Opening the Stock Market to Everyone. Here's What That Actually Means
Jason CalacanisChamath PalihapitiyaPaul AtkinsMichael Selig
SEC Chair Atkins wants to restore the IPO as a financing round through material-disclosure reform, less litigation, and review of quarterly reporting and accreditation rules.CFTC Chair Selig is replacing regulation by enforcement with purpose-fit frameworks for crypto, prediction markets, AI, and blockchain, while agencies pursue coordinated oversight.Tokenization could enable T+0 settlement and broader onshore innovation, but autonomous trading, manipulation, leverage, and gambling-related harms remain unresolved monitoring risks.
Solana’s Anatoly Yakovenko on Crypto's Next Era: Quantum, AI, and the Future of Money
GENIUS Act implementation could unlock $1 trillion–$10 trillion of stablecoins on public chains, potentially making the internet the largest holder of U.S.Treasuries within five years.Solana’s proposed edge is execution speed—roughly 1,000 times faster than ETH by Yakovenko’s estimate—while tokenized securities, uncorrelated real-world assets, and Bitcoin’s quantum migration remain regulation- and infrastructure-dependent catalysts.
DOGE vs USAID, Crypto Framework, Google's $75B AI Spend, US Sovereign Wealth Fund, GLP-1s
Chamath PalihapitiyaJason CalacanisDavid SacksDavid FriedbergAntonio Gracias
Crypto’s policy path is stablecoin legislation followed by a FIT21-style market-structure bill, with Sacks citing alignment among all four relevant committee chairs and passage within several months as plausible.Google’s $75B 2025 capex plan looks like a utilization and ROIC test: a 20% return plus six-year amortization requires roughly $27B in incremental annual operating profit.A US sovereign wealth fund remains divided between strategic reinvestment and disciplined asset sales, while GLP-1 benefits and muscle and bone-density loss remain unresolved.


